IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Li cens ing: In 2003, Novartis paid $255 mil lion for ap prox i mately 54% of pri vately-owned Idenix’s out -
stand ing cap i tal stock, gain ing rights to de velop and com mer cial ize Tyzeka (telbivudine) and other drug
can di dates dis cov ered by Idenix. Novartis was re ported to hold a 56% stake in Idenix in 2008.
VAC CINE, BORRELIA, NOVARTIS: Novartis is de vel op ing a vac cine against Borrelia for the treat ment
of Lyme dis ease. Pre clin i cal stud ies are be ing con ducted in Swit zer land.
VAC CINE, CANDIDA, NOVARTIS: Novartis is de vel op ing a vac cine against Candida in fec tion. Pre clin i -
cal stud ies are un der way in Swit zer land.
VAC CINE, CHLAMYDIA, NOVARTIS/INTERCELL: Novartis and Intercell (Aus tria) are de vel op ing a
vac cine for the pre ven tion of chlamydial in fec tions. Pre clin i cal stud ies are be ing con ducted in Switzerland.
VAC CINE, GROUP A STREP TO COC CUS, NOVARTIS: A vac cine against Group A Strep to coc cus (GAS)
was in pre clin i cal stud ies with Novartis in 2008. It is re ported to be sched uled to en ter phase I tri als in
2010. GAS causes phar yn gi tis, rheu matic fe ver and necrotizing fasicitis.
VAC CINE, GROUP B STREP TO COC CUS, NOVARTIS/INTERCELL: In De cem ber 2008, Novartis
signed a cross-li cens ing deal with Intercell (Aus tria), un der which Novartis ac quires ex clu sive rights to
Intercell’s Group B Strep to coc cus (GBS) vac cine pro gram. In re turn, Intercell re tains and re ceives co-ex -
clu sive rights to de velop monoclonal an ti bod ies against GBS, and ac quires ad di tional rights to GBS an ti -
bod ies from Novartis. This agree ment has trig gered pay ment of a rec og ni tion rev e nue from Novartis to
Intercell, un der a stra te gic part ner ship (signed in 2007). Intercell granted Novartis a li cense op tion to a
vac cine port fo lio, in clud ing the GBS vaccine program, under the strategic partnership.
VAC CINE, IN FLU ENZA, DYNAVAX: In July 2008, Dynavax (USA) an nounced a deal with Novartis for
the de vel op ment, and pos si ble com mer cial iza tion of Dynavax’s uni ver sal in flu enza vac cine. Novartis will
sup ply Dynavax with tri va lent in flu enza vac cine, a com po nent of Dynavax’s uni ver sal in flu enza vac cine,
for use in clin i cal tri als and vac cine sales. Novartis has re ceived an ex clu sive op tion to ne go ti ate a joint de -
vel op ment and com mer cial iza tion agree ment with Dynavax. Dynavax will con duct early stage de vel op -
ment through a de fined proof-of-con cept. Dynavax would re tain co-com mer cial iza tion rights in the USA
and re ceive prod uct roy al ties out side the USA if Novartis ex er cises the op tion. If the op tion is not ex er -
cised, Novartis will con tinue to sup ply Dynavax with tri va lent in flu enza vac cine and Dynavax will have the
right to con tinue with late-stage de vel op ment and com mer cial iza tion. The uni ver sal in flu enza vac cine
links Dynavax’s sec ond-gen er a tion TLR9 ag o nist (immunostimulatory DNA se quences (ISS)) to the key
in flu enza an ti gens nucleoprotein (NP), an an ti gen that var ies lit tle be tween vi ral strains or from year to
year, and to the extracellular do main of matrix protein 2 (M2e). NP-ISS and M2e-ISS are then added to a
conventional vaccine to augment its activity.
VAC CINE, KLEBSIELLA, NOVARTIS/INTERCELL: Novartis and Intercell (Aus tria) are de vel op ing a
vac cine against Klebsiella pneumoniae for the treat ment of in fec tions caused by this bac te rium. Pre clin i -
cal stud ies are be ing con ducted in Switzerland.
VAC CINE, OTITIS ME DIA, NOVARTIS/INTERCELL: Novartis and Intercell are de vel op ing a vac cine
against in fec tions that af fect the mid dle ear (otitis me dia). Pre clin i cal stud ies are un der way in
Switzerland.
VAC CINE, STREP TO COC CUS PNEUMONIAE, NOVARTIS/INTERCELL: Novartis and Intercell (Aus -
tria) are co-de vel op ing a vac cine against Strep to coc cus pneumoniae in fec tions in chil dren (a cause of
otitis me dia, pneu mo nia, bacteremia and bac te rial men in gi tis). The vac cine tar gets new and drug-re sis -
tant strains of S pneumoniae. Novartis’ set of con served pro teins are ex pected to pro vide cov er age
against a wide range of S pneumoniae strains, in clud ing drug-re sis tant strains. Pre clin i cal stud ies are on -
go ing in Swit zer land. A phase I trial is planned to begin in 2010.
© 2009 IMS Health In cor po rated or its af fil i ates Page 106